PT  - JOURNAL ARTICLE
AU  - Yet H. Khor
AU  - Elisabetta A. Renzoni
AU  - Dina Visca
AU  - Christine F. McDonald
AU  - Nicole S. L. Goh
TI  - Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns
AID  - 10.1183/23120541.00118-2019
DP  - 2019 Jul 01
TA  - ERJ Open Research
PG  - 00118-2019
VI  - 5
IP  - 3
4099  - http://openres.ersjournals.com/content/5/3/00118-2019.short
4100  - http://openres.ersjournals.com/content/5/3/00118-2019.full
SO  - erjor2019 Jul 01; 5
AB  - Domiciliary oxygen therapy is often prescribed for patients with hypoxaemia due to advanced lung disease, most commonly chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Long-term oxygen therapy (LTOT) trials conducted in patients with COPD in the 1980s remain the basis for clinical decisions and guideline recommendations regarding LTOT for patients with non-COPD conditions as there is a lack of high-quality evidence concerning its use in the non-COPD population. There is also a lack of evidence for the use of ambulatory and nocturnal oxygen therapy in patients with isolated exertional and nocturnal hypoxaemia. These deficiencies pose significant challenges in patient care, with consequent discrepancies in guideline recommendations and clinical approaches. In recent years, new studies have been and are currently being conducted to fill the gaps in our understanding and use of domiciliary oxygen therapy for other indications, including ILD. This article provides a comparison of the epidemiology and significance of hypoxaemia in patients with COPD and ILD, with an up-to-date review of current evidence regarding the role of different types of domiciliary oxygen therapy in these conditions.Despite the significance of hypoxaemia in patients with chronic lung diseases, an up-to-date review shows current evidence for clinical use of domiciliary oxygen therapy remains limited http://bit.ly/33aW31n